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Survival analysisBackground: Sex disparities are common in hypertrophic cardiomyopathy (HCM). Previous research has shown
that at time of myectomy, women are older, have greater impairment of diastolic function and more advanced
cardiac remodeling. The clinical impact of these differences is unknown.
Method: This study included 162 HCM patients (61%men) who underwent septal myectomy. Time to treatment
was calculated in relation to symptomonset and diagnosis. Pre- and post-operative echocardiographic data were
collected. Sex differenceswere assessed at baseline and in time-to-event survival analyses for the composite end-
point of all-cause mortality, cardiac transplantation, re-intervention and aborted sudden cardiac death.
Results:Womenwere generally older at time of myectomy (57 vs. 49 years, p< 0.01), with similar time to treat-
ment as measured from symptom onset (2.3 [1.3–6.0] vs. 2.8 [1.1–5.3] years, p > 0.05), but a shorter time since
diagnosis compared to men (2.6 [1.2–7.0] vs. 4.3 [2.4–8.3] years, p= 0.02). Mean wall thickness and left atrial
diameter were the same for men and women, but were higher in women when correcting for body surface
area (absolute: 20 vs. 19 mm, 48 vs 46 mm, p ≥ 0.05; corrected: 9.7 vs. 11.2 mm/m2, 23.4 vs. 26.3 mm/m2,
p<0.01). After 5.9 [3.0–9.1] years, 15% ofmen and 8% ofwomen had reached the composite endpoint (p>0.05).
Conclusion: In conclusion, although women present later in life and seem to have more advanced disease on
echocardiography, time until myectomy was similar and clinical outcomes after myectomy are favourable for
both men and women.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hypertrophic cardiomyopathy (HCM) is the most prevalent
inherited cardiac disease, with an estimated prevalence of
0.2–0.5% of the general population [1]. In HCM patients, the pres-
ence of left ventricular outflow tract (LVOT) obstruction is associ-
ated with significant morbidity and mortality [2,3]. Septal
reduction therapy is the primary treatment modality for patients
suffering from drug-refractory symptoms for obstructive HCM. Re-
cent research has shown that women are older and have morextension; HCM, hypertrophic
outflow tract; NYHA, New York
systolic anterior motion of the
ic echocardiography.
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bility and freedom from bias of
. This is an open access article under
. Schinkel, P.L. de Jong, et al.,
ional Journal of Cardiology, hadvanced disease at time of myectomy, as reflected through a
greater impairment of diastolic function and more fibrosis on mi-
croscopy [4]. These findings are in unison with the older age of di-
agnosis and more symptomatic clinical presentation often
observed in women with HCM, and are a possible indication of a
delay in surgical treatment of women [5–8]. A potential conse-
quence of this is worse clinical outcome after myectomy. How-
ever, previous research has shown that women with HCM start
to exhibit symptoms later in life [9]. Whether these age differ-
ences are therefore truly secondary to diagnostic or therapeutic
delays, rather than a reflection of an inherently different disease
process, is unknown. To better understand the temporal differ-
ences between men and women, we aimed to quantify and com-
pare time until myectomy in relation to symptom onset and
diagnosis date. Furthermore, in this study we aimed to compare
pre- and perioperative clinical characteristics as well as postoper-
ative outcome and survival of men and women undergoing septal
myectomy.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Study design
We identified 162 patients who underwent septal myectomy with-
out concomitant cardiac surgery between 2000 and 2019 in the Eras-
mus Medical Center. The diagnosis of HCM was based on a maximal
wall thickness (MWT) ≥15 mm (≥13 mm in first-degree relatives with
HCM), not explained by loading conditions, in accordance with the
guidelines [10]. Patients with HCM phenocopies, such as Anderson-
Fabry disease, Danon disease, Noonan syndrome, amyloidosis, or other
confirmed metabolic or mitochondrial disorders or malformation syn-
dromes were excluded. Patients were candidates for myectomy based
on 1) a peak LVOT gradient ≥50 mmHg at rest or after provocation
and 2) presence of unacceptable symptomsdespitemaximally tolerated
medical therapy, including beta-blocking agents and calcium channel
blockers [10]. The study conforms to the principles of the Declaration
of Helsinki. All subjects gave informed consent for inclusion in the reg-
istry and local institutional review board approval was obtained.
2.2. Surgical technique
In our center, patients with enlarged anterior mitral valve areas
(>12 cm2) are often treated by combining septal myectomywith ante-
rior mitral valve leaflet extension (AMLE). Both surgical techniques
have been described previously [11,12]. In short, after employment of
standard cardiac surgery techniques aortotomy is performed, allowing
partial resection of the septum towards the apex, leftwards of the imag-
inary line between the nadir of the right coronary cusp. An autologous
pericardial patch is then placed across the bending point of the mitral
valve to stiffen the anterior mitral valve leaflet, extending its width,
shifting the centrally located chordae laterally. As the chordae are
stretched and erected, leaflet coaptation is increased. Force of blood
flow against the leaflet (which is proportional to its area) is increased,
decreasing SAM and mitral regurgitation. The decision to perform
AMLE was based initially on pre-operative echocardiographic assess-
ment of the mitral valve leaflet area with the final decision made by
the surgeon perioperatively, based on visual inspection and epicardial
echocardiographic assessment of the mitral valve, its leaflet area and
papillary muscle length. Surgical results are assessed with transesopha-
geal echocardiography immediately after weaning from cardiopulmo-
nary bypass, at a systolic blood pressure of ≥100 mmHg.
2.3. Clinical evaluation
Pre- and post-operative clinical assessment includedmedical history
and transthoracic echocardiography (TTE). Medical history included as-
sessment of symptom status according to the New York Heart Associa-
tion (NYHA) classification and medication status. Time-to-treatment
was measured from symptom onset and from date of HCM diagnosis,
the former beingdefined by thefirst occurrence of symptomsassociated
with and judged to be caused by HCM (i.e. chest pain, dyspnea, fatigue,
palpitations, syncope or cardiac arrest) in the absence of another more
likely explanation. Both variables were considered missing when an
exact year could not be determined.
TTE was generally performed a month before surgery, at discharge
following myectomy, three months later and thereafter at yearly inter-
vals. TTE studies were analyzed according to the guidelines [10,13,14].
Peak LVOT gradient wasmeasured in rest and after provocation (partic-
ularly the Valsalva maneuver) using Doppler echocardiography and by
applying the modified Bernoulli equation, which is defined as P = 4v2,
where P is the peak gradient and v equals blood velocity. Left ventricular
(LV) systolic function was categorized as good (LV ejection fraction
>51%), mildly reduced (LV ejection fraction 41% to 51%),moderately re-
duced (LV ejection fraction 30% to 40%), and poor (LV ejection fraction
<30%) [13]. LV diastolic function was categorized as normal, abnormalPlease cite this article as: R. Huurman, A.F.L. Schinkel, P.L. de Jong, et al.,
obstructive hypertrophic cardiom..., International Journal of Cardiology, hrelaxation, pseudonormal, or restrictive filling, based on Doppler mitral
inflow pattern parameters including early (E) and late (A) LV filling ve-
locities, E/A ratio, and tissue Doppler-derived septal early diastolic ve-
locities (e’) [14].
Genetic counselling and testing is routinely offered to HCM patients
visiting the cardiogenetic outpatient clinic of the ErasmusMC and is de-
scribed previously [15]. Before 2012, genetic testingwas based on direct
sequencing targeting a subset of mutations (≤11 genes) associated with
HCM. Thereafter, next-generation sequencing covering a panel of >48
cardiomyopathy-associated genes was used, and since 2018 we
employed whole-exome sequencing. Genetic analysis in family mem-
bers of pathogenic gene mutation carriers targeted the gene mutation
identified in the proband.2.4. Follow-up
Follow-up information was obtained at routine visits at the HCM
outpatient clinic or from hospitalization records in case of complica-
tions. Registered complications include peri-operative death, condu-
ction disorders requiring pacemaker implantation, iatrogenic
ventricular septal defect, pericardial effusion requiring pericardiocen-
tesis, mediastinitis and stroke. Mortality status and causes of death
were obtained from the hospital records, from general practitioners
and by consulting civil registries. Endpoints included all-cause mortal-
ity, HCM-related mortality, cardiac transplantation, (aborted) sudden
cardiac death (SCD) and repeat septal reduction therapy. Mortality
was considered HCM-related in case of SCD, death caused by heart fail-
ure, post-operative death after an HCM intervention and stroke-related
death. SCD was defined as (1) instantaneous and unexpected death in
patients whowere previously in a stable clinical condition, or nocturnal
death with no antecedent history of worsening symptoms; (2) resusci-
tation after cardiac arrest; or (3) appropriate implantable cardioverter-
defibrillator intervention. Patients who were lost to follow-up were
censored at time of last follow-up.2.5. Statistical analysis
Values were expressed as mean ± standard deviation, median [in-
terquartile range] or number (%). Continuous data were assessed for
normality by inspecting Q-Q plots and using the Shapiro-Wilk test,
and were analyzed using the Student's t-test or Mann-Whitney U test,
as appropriate. Categorical data were compared using Pearson's χ2
test. Univariable and multivariable Cox proportional hazard regression
analyses were used to assess the effect of sex and other baseline vari-
ables on time until the composite endpoint. All baseline variables
were considered as potential predictors, but sex was entered into the
multivariable model regardless of its performance in univariable analy-
sis to account for potential suppressor effects from other independent
variables. To allow us to discern potential differences between men
and women in regard to disease progression, surrogate markers of dis-
ease progression (e.g. atrial fibrillation, systolic and diastolic dysfunc-
tion, time from disease onset) were favored over other candidate
predictors. Model assumptions were assessed by inspecting Schoenfeld
andMartingale residuals. Survival curveswere constructed according to
the Kaplan-Meier method, and comparisons were performed using the
log-rank test. We performed a secondary analysis by stratifiying the
group above and below the median time of surgery and compared age
and timeuntilmyectomy formen andwomen, in order to ascertain pos-
sible temporal differences. All testingwas two-tailed and p values<0.05
were considered statistically significant. All statistical analyses were
performed using SPSS version 22 (IBM Corp., Armonk, New York) and
R version 3.6.2 (https://cran.r-project.org/).Impact of sex on timing and clinical outcome of septal myectomy for
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Table 1
Clinical and echocardiographic variables for men and women at time of myectomy.
Variable Men
(n = 99)
Women
(n = 63)
P
value
Age (y) 49 ± 14 57 ± 15 <0.01
NYHA class 0.78
I 1 (1%) 1 (2%)
II 20 (21%) 12 (19%)
III 75 (77%) 48 (76%)
IV 1 (1%) 2 (3%)
Atrial fibrillation 20 (20%) 12 (19%) 0.86
Hypertension 27 (27%) 29 (46%) 0.01
Hypercholesterolemia 18 (18%) 22 (35%) 0.02
Diabetes mellitus 9 (9%) 7 (11%) 0.67
Pathogenic DNA variant* 36 (41%) 17 (34%) 0.42
Beta-blockers 76 (77%) 47 (77%) 0.97
Calcium channel antagonists 41 (41%) 26 (43%) 0.88
Disopyramide 2 (2%) 2 (3%) 0.62
ACE inhibitors or angiotensin II receptor
blockers
9 (9%) 16 (25%) <0.01
Mineralocorticoid receptor antagonists 1 (1%) 4 (7%) 0.07
Diuretics 14 (14%) 11 (18%) 0.51
Implantable cardioverter-defibrillator 15 (15%) 7 (11%) 0.46
Time-to-treatment†
Whole group
(n = 149)
from symptom
onset (y)
2.8 [1.1 – 5.3] 2.3 [1.3 – 6.0] 0.82
from diagnosis
(y)
4.3 [2.4 – 8.3] 2.6 [1.2 – 7.0] 0.02
Initial evaluation for
symptoms (n = 89)
from symptom
onset (y)
3.4 [1.4 – 6.2] 3.4 [1.7 – 7.0] 0.69
from diagnosis
(y)
3.0 [1.2 – 6.0] 1.7 [0.9 – 4.2] 0.25
Initial evaluation for
other reasons
(n = 60)
from symptom
onset (y)
1.4 [0.6 – 4.4] 1.7 [0.9 – 2.7] 0.81
from diagnosis
(y)
7.5 [4.0 – 11.6] 3.1 [1.4 – 8.5] 0.01
Echocardiographic variables
Peak resting or provoked LVOT gradient
(mmHg)
82 ± 33 93 ± 34 0.04
Maximal wall
thickness
absolute (mm) 20 ± 5 19 ± 5 0.58
indexed
(mm/m²)
9.7 ± 2.5 11.2 ± 4.6 <0.01
LA diameter absolute (mm) 48 ± 7 46 ± 7 0.05
indexed
(mm/m²)
23.4 ± 3.6 26.3 ± 7.8 <0.01
LV end-diastolic
diameter
absolute (mm) 45 ± 8 42 ± 5 0.01
indexed
(mm/m²)
22.2 ± 3.7 23.4 ± 3.0 0.09
Systolic function‡ 0.80
Good 88 (92%) 54 (89%)
Mildly reduced 7 (7%) 6 (10%)
Moderately
reduced
1 (1%) 1 (2%)
Diastolic function§ 0.29
Normal 16 (16%) 4 (6%)
Impaired
relaxation
28 (29%) 22 (35%)
Pseudonormal
relaxation
47 (48%) 33 (52%)
Restrictive 7 (7%) 4 (6%)
Systolic anterior motion of the mitral
valve
96 (98%) 62 (100%) 0.26
Mitral regurgitation 0.94
No/trace 8 (8%) 5 (8%)
Mild/moderate 77 (80%) 47 (78%)
Severe 11 (12%) 8 (13%)
Data are presented as number (percentage), mean ± SD or median [IQR]. *Proportion of
genotype-positive patients of genetically tested group. †Date of symptom onset and diag-
nosis was available in 133 and 161 patients, respectively. 54 (54%) men and 35 (65%)
women were initially evaluated for symptoms. Other reasons include family screening
(7 [7%] men and 2 [4%] women) or incidental findings (33 [35%] men and 18 [33%]
women). ‡Systolic function could not be assessed in 3 (3%) men and 2 (3%) women.
§ Diastolic function could not be assessed in 1 (1%) man. ACE = angiotensin converting
enzyme, HCM = hypertrophic cardiomyopathy, LA = left atrial, LV = left ventricular,
LVOT = left ventricular outflow tract, NYHA = New York Heart Association.
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3.1. Study cohort
Baseline characteristics for men and women are presented in
Table 1. On average, women were 8 years older at time of myectomy.
In the full group, time untilmyectomy asmeasured fromdate of diagno-
sis was higher inmen. Time until myectomywas similar in the subset of
patients initially evaluated for symptoms. Year of symptom onset was
missing in 14 (14%)men and11 (18%)women, and the year of diagnosis
was unknown in 1 man and 1 woman. Sex was not a predictor of miss-
ing symptom onset or diagnosis data (odds ratio for male sex 0.78
[0.33–1.84]).
More than a third of both men and women had a pathogenic sarco-
meric gene variant. Female patients weremore likely to have hypercho-
lesterolemia and hypertension, and used angiotensin-converting
enzyme-inhibitors or angiotensin II receptor blockers more often.
When comparing absolute values, MWT and left atrial diameter were
similar for men and women and LV end-diastolic diameter was higher
in men. Corrected for body surface area (BSA), LV end-diastolic diame-
ter was similar, but MWT and left atrial diameter were higher in
women. Diastolic function was impaired in 84% of men and 94% of
women (p > 0.05).
3.2. Surgical results
Globally, no differences were seen regarding post-operative results
(Table 2). Clinical improvement (i.e. reduction in NYHA class ≥1) was
achieved in the majority (≥94%) of both men and women. Echocardio-
graphic results were slightly in favor of men, who had a lower median
post-operative LVOT gradient and a higher relative gradient reduction.
The LVOT obstruction was abolished in 91% of men and 81% of
women, although this did not reach statistical significance. No differ-
ences were seen regarding length of stay and complication rate, both
in total and for individual complications.
3.3. Clinical outcome
Unadjusted Kaplan-Meier survival curves for the composite end-
point of all-cause mortality, cardiac transplantation, repeat septal re-
duction therapy and aborted SCD are shown in Fig. 1A. After a median
follow-up of 5.9 [3.0–9.1] years, 15% ofmen and 8%women had reached
the composite endpoint (log-rank: p = 0.27), demonstrating similar
survival after myectomy for both sexes. Age-adjusted survival rates di-
verged early in favor of women, although the difference was not signif-
icant (p=0.067, Fig. 1B). Table 2 illustrates the occurrence of individual
endpoints for men and women. In univariable Cox proportional hazard
regression analyses, sex was not a predictor of outcome, whereas age,
heart failure medication and degree of diastolic dysfunction were. Use
of heart failure medication and diastolic dysfunction were significant
predictors after multivariable adjustment (Table 3).
3.4. Temporal differences
To explore temporal differences whilst preserving sample size, we
split the group below and above the median time of surgery (August
2012). Men were relatively overrepresented in both periods (before
and after 2012: 56% vs. 67%, p=0.15). Therewere no significant age dif-
ferences comparing men and women separately between periods
(men: 47 ± 13 vs. 52 ± 14 years, p = 0.10; women: 55 ± 17 vs.
58± 14 years, p=0.51), although overall the recent group was several
years older (50± 15 vs. 55± 15 years, p=0.047). No differences were
found when comparing time until myectomy in men before and after
2012 (from symptom onset: 3.7 [1.2–6.4] vs. 2.2 [1.1–4.5] years; from
diagnosis: 6.0 [2.7–9.3] vs. 4.0 [2.0–7.4] years, p > 0.05 for both), nor
in women before and after 2012 (from symptom onset: 2.9 [1.4–7.8]Please cite this article as: R. Huurman, A.F.L. Schinkel, P.L. de Jong, et al., Impact of sex on timing and clinical outcome of septal myectomy for
obstructive hypertrophic cardiom..., International Journal of Cardiology, https://doi.org/10.1016/j.ijcard.2020.08.059
Table 2
Post-operative outcome after myectomy stratified according to sex.
Variable Men
(n = 99)
Women
(n = 63)
P
value
Improvement in symptoms* 82 (95%) 46 (94%) 0.71
Peak LVOT gradient (mmHg)† 10 [7–18] 19 [10–38] 0.001
LVOT gradient reduction (mmHg)† 65 [45–80] 68 [36–81] 0.91
LVOT gradient reduction (%)† 86 [69–92] 77 [55–86] <0.01
Post-operative LVOT gradient ≥30 mmHg 9 (9%) 12 (19%) 0.07
AMLE performed‡ 76 (78%) 38 (62%) 0.04
Complications 17 (18%) 9 (14%) 0.59
Peri-operative mortality 0 (0%) 1 (2%) 0.21
Mediastinitis 3 (3%) 0 (0%) 0.16
Ventricular septal defect 1 (1%) 0 (0%) 0.42
Pericardial effusion requiring drainage 14 (14%) 5 (8%) 0.39
Conduction disturbance requiring pacing 3 (3%) 3 (5%) 0.59
Stroke 0 (0%) 0 (0%) –
Length of hospital stay (days) 8 [7–9] 9 [6–10] 0.46
Outcome
Repeat septal reduction therapy 2 (2%) 0 (0%)
Aborted sudden cardiac death 2 (2%) 0 (0%)
All-cause mortality 10 (10%) 5 (8%)
Peri-operative mortality 0 (0%) 1 (1%)
Sudden cardiac death 1 (1%) 0 (0%)
HCM-related death 0 (0%) 2 (3%)
Non-cardiac death 3 (3%) 0 (0%)
Unknown 6 (6%) 2 (3%)
Cardiac transplantation 1 (1%) 0 (0%)
Data are presented as number (percentage), mean± SD ormedian [IQR]. *defined as a re-
duction of ≥1 New York Heart Association functional class, assessed at routine follow-up
after 3 months. †measured on transthoracic echocardiography at routine follow-up after
3 months. ‡unknown in 1 man and 2 women. AMLE = anterior mitral leaflet extension;
HCM= hypertrophic cardiomyopathy; LVOT = left ventricular outflow tract.
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years, p > 0.05 for both).
4. Discussion
This study demonstrates that, despite apparent differences at time of
surgery, survival after myectomy is the same for both men and women
after a median follow-up of 6 years. The most prominent differences
found in our study are that women are 8 years older at time of surgery,
that they seem to exhibit more advanced disease on echocardiography,
and that both pre- and post-operative LVOT gradients were higher in
women. Time until myectomy was similar in men and women.
4.1. Sex differences
This study was primarily conducted following the results of a recent
study done by Nijenkamp et al., which was done on a subset of patients
of our current cohort [4]. In that study, tissue of the ventricular septum
of 27 women and 44 men was obtained during myectomy, after which
isometric force measurements, protein analyses and histomorphol-
ogical analyses were performed. Their findings were in part similar to
the current results, with women being older at time of surgery and hav-
ing higher indexed echocardiographic indices. Additionally, there was
more interstitial fibrosis comparing women to men, altogether indicat-
ing more severe diastolic impairment on a cellular level and, as such,
more severe disease at time of myectomy. These findings may indicate
a delayed treatment in women, potentially influencing clinical out-
comes following myectomy. The current findings demonstrate that, in
a cohort of 99 men and 63 women, no differences in clinical outcome
exist after a median follow-up of 6 years.
Potential sex differences concerning survival after myectomy have
been investigated by several studies [5,16,17]. A recent study byMeghji
et al. on 2506 patients demonstrated worse survival in women in their
unadjusted analysis [16]. However, this difference was not found after
adjustment for baseline characteristics. In contrast, Woo et al. foundPlease cite this article as: R. Huurman, A.F.L. Schinkel, P.L. de Jong, et al.,
obstructive hypertrophic cardiom..., International Journal of Cardiology, hfemale sex to be an independent predictor of mortality in 338 patients
[17]. The reasons for the differing results are unclear. Two findings are
notable:first, all patients included in the latter study underwent surgery
before 2002. Under the assumption that women are recognized and di-
agnosed at a later age (and thus later in their disease process), it is pos-
sible that studies conducted earlier in timewill have a higher proportion
of late-diagnosed women compared to contemporary research per-
formed on data of an era inwhichmore awareness of sex-specific biases
exists. Itmust be noted that in their study, female sexwas only a predic-
tor of outcome after multivariable adjustment (and not in univariable
analysis), which could signify that female sex asserts its effects on out-
come by mediating other variables (e.g. age) rather than by its own as-
sociation with outcome. Furthermore, surgical technique and
experience as well as post-operative care will likely have improved in
this time (which is reflected in the study by Meghji et al. by improved
survival following more recent surgery), although we do not consider
it likely that this alters sex related differences. Second, in the study by
Meghji et al., similar to our results, the median age of women was sev-
eral years higher compared to men. As age was the strongest predictor
of mortality in their adjusted analysis, the sex difference seen in the un-
adjusted analysis likely stems from this age gap.
Interestingly, in their study and in that of Rowin et al., similarly
reporting on sex differences in a large HCM center, women undergoing
septal myectomy had more advanced symptoms compared tomen (re-
spectively NYHA III/IV 91% vs 85% and a mean NYHA class 2.4 ± 0.7 vs
2.1 ± 0.8), a finding not reproduced in our study. There is no obvious
explanation for this difference, especially since both European and
American guideline recommendations on timing of myectomy are sim-
ilar [10,18]. Potential differences in NYHA assessment might be of im-
portance, as we reported NYHA class at last assessment prior to
surgery, and in both other studies it seems possible that this was done
at an earlier moment. Differences in referral patterns can similarly be
relevant and the influence of sample size can also not be excluded. Re-
gardless, since a higher NYHA class was an independent predictor of ad-
verse outcome in the study byMeghji et al., this represents an important
topic both in the appreciation of sex differences and in general HCM
care. The question remains whether survival would improve if women
(but also men) are diagnosed and treated earlier in the disease process,
when there is a lower symptomatic burden. Performing septal reduc-
tion therapy at an earlier stage (i.e. in patients with NYHA II symptoms)
is a topic worthy of consideration, but this would require methods of
identifying patients with a higher risk of progressing to severe symp-
toms, which we currently lack.
Sex-related differences in HCMare gainingmore interest in contem-
porary literature [6–9,19–23]. Women are often under-represented in
HCM cohorts, giving rise to amyriad of potential explanationswhich in-
clude, but are not limited to, a diagnostic bias, referral bias, a decreased
awareness of cardiovascular disease and accompanying symptoms in
womenboth in patients andmedical professionals, and biological differ-
ences in sex hormone receptor levels and gene expression. A near-
universal finding in multiple cohorts is a higher age in women com-
pared tomen, whether this is at initial evaluation or at time of interven-
tion [4–9,19,20]. The reasons for this age discrepancy as well as its
implications in the context of diagnostic and therapeutic delays are con-
troversial topics. In this study,menwere diagnosed at a younger age rel-
ative to their time of surgery. This is likely explained by differences in
the modes of presentation expanded upon in several studies, which
givemenmore, earlier opportunities for thedetection of HCM [5–8]. Im-
portantly, this difference was not seen in the subset of patients initially
evaluated for symptoms, which demonstrates that their clinical course
is broadly similar as soon as they are identified as patients. Moreover,
time from symptom onset until surgery was equal for men and
women, which suggests that a hypothesized diagnostic bias does not
confer a therapeutic delay. Dimitrow et al. found that age of symptom
onset was later in HCM women compared to men (31 ± 12 vs. 27 ±
10 years) with women also being more likely to present beyond theImpact of sex on timing and clinical outcome of septal myectomy for
ttps://doi.org/10.1016/j.ijcard.2020.08.059
Fig. 1.Kaplan-Meier survival curves for the composite endpoint of all-causemortality, cardiac transplantation, repeat septal reduction therapy and aborted sudden cardiac death stratified
by sex. A, unadjusted survival curves formen (blue) andwomen (red). B, survival curves formen (blue) andwomen (red) adjusted (Cox-Kalbfleisch-Prentice) for age. No differenceswere
seen regarding event-free survival after amedian follow-upof 5.9 [3.0–9.1] years (unadjusted: p=0.27, adjusted: p=0.067). Shaded areas represent 95% confidence intervals. Prevalence
of individual endpoints is shown in Table 2. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Table 3
Results of univariable and multivariable Cox proportional hazard regression analysis of
baseline characteristics.
Variable Univariable HR
[95% CI]
P value Multivariable
HR [95% CI]
P
value
Male sex 1.75
[0.63–4.85]
0.28 2.32 [0.79–6.83] 0.13
Age (y) 1.04
[1.00–1.07]
0.03 1.03 [0.99–1.07] 0.17
NYHA class ≥III 1.24
[0.57–3.33]
0.66
Atrial fibrillation 1.71
[0.66–4.46]
0.27
Hypertension 0.86
[0.31–2.39]
0.78
Hypercholesterolemia 0.95
[0.32–2.86]
0.93
Diabetes mellitus 1.23
[0.28–5.30]
0.79
Pathogenic DNA variant 0.31
[0.09–1.07]
0.06
Negative inotropic therapy* 0.38
[0.14–1.04]
0.06
Heart failure therapy† 5.32
[2.03–13.94]
0.001 3.58 [1.29–9.93] 0.01
Implantable
cardioverter-defibrillator
0.53
[0.12–2.30]
0.39
Time from symptom onset
(y)
0.97
[0.86–1.10]
0.60
Time from diagnosis (y) 0.99
[0.91–1.08]
0.83
Pre-operative peak LVOT
gradient (mmHg)
1.00
[0.98–1.01]
0.68
Maximal wall thickness
absolute (mm) 1.03
[0.95–1.12]
0.50
indexed (mm/m2) 0.98
[0.88–1.09]
0.71
LA diameter
absolute (mm) 1.04
[0.98–1.11]
0.16
indexed (mm/m2) 1.00
[0.95–1.05]
0.99
LV end-diastolic diameter
absolute (mm) 1.03
[0.94–1.12]
0.57
indexed (mm/m2) 1.05
[0.89–1.24]
0.58
Impaired systolic function 0.48
[0.06–3.70]
0.48
Diastolic function‡ 3.04 [1.38–6.70] <0.01
Normal reference
Impaired relaxation 2.12
[0.42–20.72]
0.38
Pseudonormal relaxation 3.72
[0.83–35.38]
0.09
Restrictive 23.15
[3.80–250.71]
<0.001
Systolic anterior motion of
the mitral valve
0.17
[0.02–1.32]
0.09
Mitral regurgitation
No/trace reference
Mild/moderate 0.33
[0.10–1.04]
0.06
Severe 0.37
[0.09–1.57]
0.18
*includes beta-blockers, non-dihydropyridine calcium-channel antagonists and
disopyramide. †includes angiotensin-converting enzyme inhibitors, mineralocorticoid re-
ceptor antagonists and diuretics, ‡univariable HR calculated using Firth's penalized maxi-
mum likelihood bias reduction method to account for data separation, treated as linear
term in multivariable analysis. HR = hazard ratio; NYHA= New York Heart Association.
6 R. Huurman et al. / International Journal of Cardiology xxx (2020) xxxage of 40 [9]. Based on those results andour findings, we believe that the
older age of women in our cohort is not purely a consequence of differ-
ent forms of bias causing a treatment delay, and that it should be consid-
ered that the clinical course of HCM inherently implies a delayeddisease
onset in women.Please cite this article as: R. Huurman, A.F.L. Schinkel, P.L. de Jong, et al.,
obstructive hypertrophic cardiom..., International Journal of Cardiology, h4.2. Limitations
This study has several limitations. The retrospective nature of this
study has inherent limitations, in particular regarding the time intervals
measured until surgery. However, in an attempt to improve reliability,
data was considered missing whenever no exact year of diagnosis or
symptom onset could be ascertained. Furthermore, although the higher
BSA-indexed echocardiographic parameters in women suggest more
advanced disease, we underline the uncertainty that exists regarding
the accuracy of using BSA when scaling cardiac size and advise caution
in interpreting these results [24,25]. Also, importantly, the suggestion
that HCM ismore advanced in the female patients in our study is contra-
dictory to the hypothesis that HCM manifests itself later in life in
women, unless, for unknown reasons, female patients would be subject
to an accelerated rate of disease progression. Of note, the finding that
AMLE is performed more often in men could suggest that differences
in body size impact clinical decision-making, as the decision to perform
AMLE or not is at least in part dependent on visual inspection of the
anatomy of the LV, mitral valve and papillary muscles. Whether this is
indeed sex- and body size-specific andwhether thiswould impact prog-
nosis could not be reliably assessed in the current study and is a subject
worthy of further scrutiny. Lastly, although we only included patients
from 2000 onwards, we cannot exclude the possibility that our results
were influenced by advances in diagnostic, surgical and other therapeu-
tic techniques, or changes in the recognition of HCMdiagnoses spanning
two decades.5. Conclusion
Women undergo septal myectomy later in life and seem to have
more advanced disease on echocardiography. However, time until
myectomy was not longer, suggesting that the age difference is not
solely a function of treatment delay. Clinical outcomes after myectomy
are favourable for both men and women.
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